Oculis Stock Price, News & Analysis (NASDAQ:OCS) $9.99 +0.17 (+1.73%) (As of 12/1/2023 ET) Add Compare Share Share Today's Range$9.90▼$10.3550-Day Range$9.10▼$11.7552-Week Range$6.26▼$14.50Volume3,547 shsAverage Volume17,165 shsMarket Capitalization$363.54 millionP/E RatioN/ADividend YieldN/APrice Target$34.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial Media Oculis MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside240.3% Upside$34.00 Price TargetShort InterestHealthy0.12% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.36Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($2.97) to ($1.59) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.19 out of 5 starsMedical Sector405th out of 951 stocksPharmaceutical Preparations Industry173rd out of 431 stocks 3.5 Analyst's Opinion Consensus RatingOculis has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 8 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $34.00, Oculis has a forecasted upside of 240.3% from its current price of $9.99.Amount of Analyst CoverageOculis has only been the subject of 2 research reports in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.12% of the float of Oculis has been sold short.Short Interest Ratio / Days to CoverOculis has a short interest ratio ("days to cover") of 1.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Oculis has recently decreased by 10.15%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldOculis does not currently pay a dividend.Dividend GrowthOculis does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for OCS. Previous Next 3.0 News and Social Media Coverage News SentimentOculis has a news sentiment score of 1.36. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.76 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Oculis this week, compared to 1 article on an average week. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Oculis insiders have not sold or bought any company stock.Percentage Held by InstitutionsOnly 14.28% of the stock of Oculis is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Oculis are expected to grow in the coming year, from ($2.97) to ($1.59) per share.Price to Book Value per Share RatioOculis has a P/B Ratio of 3.05. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Oculis Stock (NASDAQ:OCS)Oculis Holding AG, a clinical-stage biopharmaceutical company, develops novel topical treatments for ophthalmic diseases for both back- and front-of-the-eye. The company's lead candidate is OCS-01, a topical dexamethasone formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for keratoconjunctivitis sicca, or dry eye disease; and OCS-05, a novel neuroprotective agent for acute optic neuritis and other neuro-ophtha disorders, such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The company is based in Zug, Switzerland.Read More OCS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart OCS Stock News HeadlinesNovember 30, 2023 | finance.yahoo.comOculis Holding AG's (NASDAQ:OCS) top owners are individual investors with 48% stake, while 30% is held by private equity firmsNovember 17, 2023 | markets.businessinsider.comBuy Rating for Oculis Holding’s Stock: Promising Pipeline Developments and Financial Health Bolster Positive OutlookDecember 3, 2023 | DTI Trader (Ad)New CBOE “special perk” helps traders target income every weekendYou might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange. November 17, 2023 | markets.businessinsider.comWedbush Reaffirms Their Buy Rating on Oculis Holding (OCS)November 15, 2023 | finanznachrichten.deOculis Holding AG: Oculis Reports Q3 2023 Financial Results and Provides Company UpdateNovember 15, 2023 | finanznachrichten.deOculis Operations Sarl: Oculis Reports Q3 2023 Financial Results and Provides Company UpdateNovember 15, 2023 | finance.yahoo.comOculis Reports Q3 2023 Financial Results and Provides Company UpdateNovember 8, 2023 | finance.yahoo.comOculis to Present at Upcoming November Investor ConferencesDecember 3, 2023 | DTI Trader (Ad)New CBOE “special perk” helps traders target income every weekendYou might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange. November 1, 2023 | finance.yahoo.comOculis to Present a Late-Breaking Abstract at the American Academy of Ophthalmology 2023 Annual Meeting on the Positive Stage 1 Results from Phase 3 DIAMOND Trial for Diabetic Macular EdemaOctober 10, 2023 | finance.yahoo.comPositive Phase 3 Stage 1 DIAMOND Trial Results of OCS-01 in Diabetic Macular Edema Presented at 23rd EURETINA CongressOctober 5, 2023 | msn.comStifel Initiates Coverage of Oculis Holding (OCS) with Buy RecommendationOctober 5, 2023 | markets.businessinsider.comWhat 4 Analyst Ratings Have To Say About Oculis HoldingOctober 5, 2023 | finance.yahoo.comOculis to Present a Late-Breaking Abstract at the 23rd EURETINA Congress on Positive Phase 3 Stage 1 DIAMOND Trial Results for Diabetic Macular EdemaSeptember 24, 2023 | barrons.comOculis Holding AG WtSeptember 14, 2023 | investing.comOculis Holding AG (OCS)September 11, 2023 | finance.yahoo.comOculis Expands its Executive Leadership Team and Appoints Rebecca Weil, Ph.D. as Chief Commercial Officer as it Enters Pre-Commercial PhaseAugust 30, 2023 | msn.comB of A Securities Maintains Oculis Holding (OCS) Buy RecommendationAugust 30, 2023 | markets.businessinsider.comExpert Ratings for Oculis HoldingAugust 30, 2023 | finance.yahoo.comOculis to Present at Upcoming September Investor ConferencesAugust 29, 2023 | finanznachrichten.deOculis Holding AG: Oculis Reports Q2 and First Half 2023 Financial Results and Provides Company UpdateAugust 29, 2023 | finance.yahoo.comOculis Reports Q2 and First Half 2023 Financial Results and Provides Company UpdateAugust 17, 2023 | msn.comOculis: Swiss Pharma With Excellent Data, Unclear FundamentalsAugust 8, 2023 | finance.yahoo.comOCS-01, First Investigational Eye Drop for Front and Back of the Eye, Met Both Primary Endpoints in Phase 3 OPTIMIZE Trial with a Once Daily Regimen for the Treatment of Inflammation and Pain Following Cataract SurgeryAugust 4, 2023 | msn.comHC Wainwright & Co. Reiterates Oculis Holding (OCS) Buy RecommendationAugust 3, 2023 | msn.comOculis enrols first patient in trial of its OCS-01 eye dropsAugust 2, 2023 | finance.yahoo.comFirst Patient Enrolled in LEOPARD, an Investigator-Initiated Trial, with OCS-01 Eye Drops for the Treatment of Cystoid Macular EdemaSee More Headlines Receive OCS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Oculis and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/15/2023Today12/02/2023Fiscal Year End12/31/2023Next Earnings (Estimated)2/21/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:OCS CUSIPN/A CIK1953530 Webwww.oculis.com Phone41-21-711-3970FaxN/AEmployees28Year FoundedN/APrice Target and Rating Average Stock Price Target$34.00 High Stock Price Target$64.00 Low Stock Price Target$23.00 Potential Upside/Downside+240.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity Ratio0.01 Current Ratio5.21 Quick Ratio5.21 Sales & Book Value Annual Sales$960,000.00 Price / Sales378.68 Cash FlowN/A Price / Cash FlowN/A Book Value$3.28 per share Price / Book3.05Miscellaneous Outstanding Shares36,390,000Free FloatN/AMarket Cap$363.54 million OptionableNot Optionable BetaN/A 7 Energy Stocks to Buy and Hold ForeverDo you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.Get This Free Report Key ExecutivesDr. Riad Sherif M.B.A. (Age 55)M.D., CEO & Director Ms. Sylvia Cheung (Age 48)Chief Financial Officer Mr. Weibo Ding (Age 52)Global COO & GM of China Dr. Bastian Dehmel (Age 52)Chief Development Officer & Head of Development Dr. Joanne Chang M.D. (Age 62)Ph.D., Head of Medical Affairs & Chief Medical Officer Mr. Páll Ragnar Jóhannesson (Age 42)Chief Strategy Officer Dr. Fang LiSenior Vice President of Regulatory AffairsMs. Rebecca WeilChief Commercial OfficerMore ExecutivesKey CompetitorsOrganogenesisNASDAQ:ORGOBiomea FusionNASDAQ:BMEAMarinus PharmaceuticalsNASDAQ:MRNSIGM BiosciencesNASDAQ:IGMSNature's Sunshine ProductsNASDAQ:NATRView All CompetitorsInstitutional OwnershipPivotal bioVenture Partners Investment Advisor LLCSold 162,442 shares on 11/14/2023Ownership: 6.097%Nan Fung Group Holdings LtdSold 44,416 shares on 11/14/2023Ownership: 1.667%Wolverine Asset Management LLCBought 7,021 shares on 11/13/2023Ownership: 0.019%Barclays PLCBought 3,602 shares on 9/21/2023Ownership: 0.010%View All Institutional Transactions OCS Stock Analysis - Frequently Asked Questions Should I buy or sell Oculis stock right now? 8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Oculis in the last year. There are currently 8 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" OCS shares. View OCS analyst ratings or view top-rated stocks. What is Oculis' stock price target for 2024? 8 analysts have issued twelve-month price targets for Oculis' stock. Their OCS share price targets range from $23.00 to $64.00. On average, they predict the company's stock price to reach $34.00 in the next year. This suggests a possible upside of 240.3% from the stock's current price. View analysts price targets for OCS or view top-rated stocks among Wall Street analysts. How have OCS shares performed in 2023? Oculis' stock was trading at $9.2122 at the beginning of the year. Since then, OCS shares have increased by 8.4% and is now trading at $9.99. View the best growth stocks for 2023 here. When is Oculis' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, February 21st 2024. View our OCS earnings forecast. How were Oculis' earnings last quarter? Oculis Holding AG (NASDAQ:OCS) posted its quarterly earnings results on Wednesday, November, 15th. The company reported ($0.38) EPS for the quarter, missing analysts' consensus estimates of ($0.36) by $0.02. The business earned $0.25 million during the quarter, compared to analysts' expectations of $0.30 million. Who are Oculis' major shareholders? Oculis' stock is owned by many different institutional and retail investors. Top institutional investors include Pivotal bioVenture Partners Investment Advisor LLC (6.10%), Nan Fung Group Holdings Ltd (1.67%) and Wolverine Asset Management LLC (0.02%). How do I buy shares of Oculis? Shares of OCS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (NASDAQ:OCS) was last updated on 12/3/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oculis Holding AG Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.